AGENUS INC. Board Member Marco Marcucci Exercises Modest Stock‑Option Grant, Signaling Confidence in Company’s Immuno‑Oncology Growth.
Insider Marcucci’s 7,500‑share option grant at AGENUS signals board confidence and potential upside amid the company’s rising immuno‑oncology pipeline.
3 minutes to read